Michiel S. van der Heijden

机构：Dutch Cancer Society, The Netherlands Cancer Institute, Oncode Institute, NMi Certin B.V. · ORCID：0000-0002-4407-7881

发表论文 353 篇 · 总被引 28019 次 · h-index 55

代表论文

• Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial (2025 · Annals of Oncology · 被引 70)
• TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study (2025 · Journal of Clinical Oncology · 被引 45)
• The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types (2025 · Nature Cancer · 被引 41)
• Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study (2025 · The Lancet Oncology · 被引 31)
• Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (2025 · ESMO Open · 被引 17)
• Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial (2025 · European Urology · 被引 10)